US Geographic Atrophy GA Market Overview:
As per MRFR analysis, the US Geographic Atrophy GA Market Size was estimated at 5.29 (USD Billion) in 2023. The US Geographic Atrophy GA Market Industry is expected to grow from 5.75(USD Billion) in 2024 to 12.5 (USD Billion) by 2035. The US Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 7.314% during the forecast period (2025 - 2035).
Key US Geographic Atrophy GA Market Trends Highlighted
The US Geographic Atrophy (GA) market is currently experiencing significant transformation driven by advancements in treatment options and increasing awareness of the disease. One of the key market drivers is the rising prevalence of age-related macular degeneration (AMD), particularly among the aging population. The Centers for Disease Control and Prevention (CDC) notes that the incidence of AMD is projected to rise sharply as the baby boomer generation ages, leading to a greater need for effective management strategies for GA. There are notable opportunities to be explored within this market, particularly in the development of innovative therapies and technologies.Gene therapy and retinal implants are gaining traction as potential treatments that may offer hope to patients suffering from GA. As research continues, pharmaceutical and biotechnological companies are focusing on clinical trials aimed at demonstrating the efficacy of new treatment modalities, thus expanding the therapeutic landscape for geographic atrophy. In recent times, there is a growing emphasis on early diagnosis and preventive care for GA. The integration of advanced diagnostic technologies such as optical coherence tomography (OCT) has improved detection rates, enabling earlier intervention. Moreover, educational initiatives aimed at both healthcare professionals and patients are helping to enhance awareness regarding the symptoms and risk factors associated with GA.This increased understanding is crucial as it encourages timely medical consultations, potentially leading to better outcomes for patients. Overall, the US Geographic Atrophy market is characterized by a convergence of technological advancements, demographic changes, and an enhanced focus on early detection, marking a dynamic shift in how this eye condition is managed and treated in the coming years.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
US Geographic Atrophy GA Market Drivers
Increasing Aging Population
The United States is experiencing a significant demographic shift, with a growing percentage of its population entering the elderly age bracket. This demographic trend is crucial for the US Geographic Atrophy GA Market Industry because age is a major risk factor for geographic atrophy, a progressive condition leading to severe vision loss. According to the U.S. Census Bureau, by 2030, approximately 20% of the U.S. population will be aged 65 or older.This increase in the aging population directly correlates with higher incidences of age-related macular degeneration, including geographic atrophy. The American Academy of Ophthalmology has projected that the prevalence of age-related macular degeneration in adults over 50 years will increase by nearly 50% between 2015 and 2050, further driving the need for effective treatment and management options in the US Geographic Atrophy GA Market Industry.
Advancements in Research and Development
There has been notable progress in the Research and Development (R&D) sector concerning treatments and therapies for geographic atrophy in the United States. Major pharmaceutical companies, such as Genentech and Regeneron Pharmaceuticals, have been actively investing in novel treatment options, including gene therapy and other innovative therapies aimed at treating retinal diseases. The National Institutes of Health (NIH) reported that funding allocated for eye disease research has seen a steady increase, amounting to over USD 700 million in 2022 alone.These investments not only advance the understanding of geographic atrophy but also facilitate the development of new products, enhancing the overall US Geographic Atrophy GA Market Industry landscape.
Growing Awareness and Early Diagnosis Initiatives
The rise in public awareness and the implementation of early diagnosis initiatives significantly support the US Geographic Atrophy GA Market Industry. Health organizations and non-profits, such as the Retina Society and the Foundation Fighting Blindness, have increased efforts in educating patients and healthcare professionals about the risks and symptoms of geographic atrophy. Increasing awareness has been associated with improved screening rates, with the American Optometric Association estimating that over 40% of individuals with vision impairment are unaware of their condition.When conditions are caught earlier, the management options and outcomes often improve, leading to a growing market for geographic atrophy treatments in the US.
US Geographic Atrophy GA Market Segment Insights:
Geographic Atrophy GA Market Age Group Insights
The Age Group segment of the US Geographic Atrophy GA Market is characterized by a significant focus on older populations, particularly individuals Above 60 Years and Above 75 Years. This demographic is critical due to the increasing prevalence of Geographic Atrophy, which is more commonly diagnosed in older adults. With the aging population in the United States, driven by advancements in healthcare and higher life expectancy, a substantial proportion of the market is driven by conditions affecting older adults. As a result, individuals above the age of 60 represent a majority holding within this market, showcasing the high risk and necessity for advanced treatment options.The segment of individuals Above 75 Years is particularly significant, experiencing a higher incidence rate of Geographic Atrophy due to cumulative health factors associated with aging. These segments not only dominate in terms of patient numbers but also highlight the evolving therapeutic landscape as industry players seek to develop more effective interventions tailored for these vulnerable age groups. The overall healthcare market continues to respond to the needs of this aging population, presenting opportunities for innovation in the treatment approaches addressing both prevention and management of Geographic Atrophy.Tailored healthcare solutions, educational initiatives, and enhanced screening strategies will be essential in catering to the specific needs of these age groups, thereby impacting the overall market dynamics powerfully. The growing awareness of eye health among older adults, supported by nutritional and lifestyle changes, also contributes to shifts in treatment demand, indicating an evolving market landscape shaped significantly by the Age Group segment. As the US population ages, the need for comprehensive management and preventive care in the Geographic Atrophy GA Market will undoubtedly shape both industry practices and patient outcomes.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Geographic Atrophy GA Market Diagnosis Insights
The Diagnosis segment of the US Geographic Atrophy GA Market is a critical area of focus, as effective diagnosis is vital for managing and treating this progressive eye disease. Employing advanced imaging technologies, such as Fundus Autofluorescence, allows for the detection of retinal changes and helps to monitor disease progression more effectively. Optical Coherence Tomography Angiography contributes to a comprehensive assessment of retinal vasculature, enabling physicians to identify abnormalities that may indicate the onset of Geographic Atrophy.Meanwhile, Multifocal Electroretinography provides vital information on retinal function, offering insights into functional impairments caused by the disease. Given that the prevalence of Geographic Atrophy is rising in the aging population, the demand for accurate diagnostic tools is increasing, creating opportunities for innovation and growth within this segment. These technologies not only enhance diagnostic accuracy but also play a significant role in shaping future treatment strategies, thereby influencing the overall landscape of the US Geographic Atrophy GA Market.As investment in Research and Development continues, advancements in these diagnostic methods are likely to foster better patient outcomes and optimize resource allocation in clinical settings.
Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights
The Therapeutic Agents Clinical Phase segment within the US Geographic Atrophy GA Market is crucial for addressing critical needs in treating this condition. As the market evolves, the Late-Stage category signifies the most promising potential therapies, showcasing innovations that could significantly improve patient outcomes. The Phase II and Phase I areas are vital for assessing efficacy and safety, often representing the transitional phase where insights gleaned from earlier stages influence final product developments. Pre-Clinical Stage research serves as the foundation for future therapeutic candidates, focusing on understanding biological mechanisms and identifying unique targets for intervention.Discovery Candidates highlight the potential for groundbreaking treatments, underscoring the importance of ongoing Research and Development activities in the market. Collaborative efforts among academia, industry, and regulatory bodies are essential to streamline the development process, ultimately leading to increased US Geographic Atrophy GA Market revenue and improving patient care landscapes. With robust investments and advancements, these segments provide vast opportunities within the market as they contribute to innovative therapeutic solutions addressing unmet medical needs.
US Geographic Atrophy GA Market Key Players and Competitive Insights:
The US Geographic Atrophy GA market is witnessing significant evolution, propelled by advancements in research and increasing investments in the development of innovative therapies aimed at slowing disease progression. Geographic Atrophy, a progressive condition linked with age-related macular degeneration, presents both challenges and opportunities for pharmaceutical companies focusing on ophthalmology. The competitive landscape is characterized by a mix of established players and emerging biotech firms, all vying to capture market share through novel treatment options and strategic partnerships. This dynamic environment is further influenced by regulatory pathways, reimbursement policies, and the growing emphasis on patient-centric care, driving companies to enhance their product offerings and operational efficiency to address unmet medical needs.Genentech has established a formidable presence in the US Geographic Atrophy GA market, focusing on research-driven initiatives aimed at developing treatments that address the complexity of this condition. The company's strength lies in its robust pipeline and commitment to innovative therapies, leveraging its extensive experience in the ophthalmology sector. Genentech’s strategic collaborations and partnerships contribute to its capability in exploring cutting-edge solutions for geographic atrophy, emphasizing the importance of clinical trials that incorporate patient feedback. The company’s established brand reputation enhances its competitive edge, enabling it to effectively engage with healthcare providers and patients while navigating the regulatory landscape to expedite the availability of its treatment options.Novartis is another key player in the US Geographic Atrophy GA market, known for its diverse portfolio that includes therapies specifically targeting ocular conditions. With a well-established presence in the pharmaceutical landscape, Novartis leverages its research and development expertise to enhance treatment protocols and improve patient outcomes in geographic atrophy management. The company’s strengths are further bolstered by its strategic mergers and acquisitions that expand its capabilities and market reach. Key products in Novartis’ pipeline demonstrate a strong focus on innovative approaches to addressing geographic atrophy, and the company's commitment to patient-centric solutions enables it to maintain competitive advantage. Through its extensive distribution network and engagement with stakeholders, Novartis effectively positions itself as a leader in delivering effective therapies for geographic atrophy in the US market.
Key Companies in the US Geographic Atrophy GA Market Include:
Genentech
Novartis
Santen Pharmaceutical
Zymeworks
Iveric Bio
EyePoint Pharmaceuticals
Bausch Health
Regeneron Pharmaceuticals
Adaptimmune
Apellis Pharmaceuticals
Amgen
Roche
AbbVie
Alkeus Pharmaceuticals
Eyenovia
US Geographic Atrophy GA Market Industry Developments
The US Geographic Atrophy (GA) Market has seen significant developments recently. In April 2023, Iveric Bio announced positive results from its Phase 3 trials for Zimura, a novel treatment targeting GA, which has since garnered attention for its therapeutic potential. In May 2023, Apellis Pharmaceuticals also reported promising data for Syfovre, its innovative therapy for GA, indicating substantial strides in the treatment landscape. Meanwhile, Genentech is actively advancing its pipeline with new compounds, focusing on innovative approaches to address retinal diseases, which has influenced market dynamics. In terms of acquisitions, in August 2023, Novartis completed its acquisition of AveXis, enhancing its capabilities in gene therapies, which may have implications for future GA treatment modalities. The market valuation for companies within the GA sector, including EyePoint Pharmaceuticals and Regeneron Pharmaceuticals, has experienced overall growth driven by advancements in Research and Development and positive clinical trial outcomes. Regulatory changes focusing on accelerated approval pathways have also fueled investor interest and market expansion, laying a promising foundation for future innovations in the US Geographic Atrophy Market.
US Geographic Atrophy GA Market Segmentation Insights
Geographic Atrophy GA Market Age Group Outlook
Above 60 Years
Above 75 Years
Geographic Atrophy GA Market Diagnosis Outlook
Fundus Autofluorescence
Optical Coherence Tomography Angiography
Multifocal Electroretinography
Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook
Late-Stage
Phase II
Phase I
Pre-Clinical Stage
Discovery Candidates
Report Scope:
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 5.29(USD Billion) |
| MARKET SIZE 2024 | 5.75(USD Billion) |
| MARKET SIZE 2035 | 12.5(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.314% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Billion |
| KEY COMPANIES PROFILED | Genentech, Novartis, Santen Pharmaceutical, Zymeworks, Iveric Bio, EyePoint Pharmaceuticals, Bausch Health, Regeneron Pharmaceuticals, Adaptimmune, Apellis Pharmaceuticals, Amgen, Roche, AbbVie, Alkeus Pharmaceuticals, Eyenovia |
| SEGMENTS COVERED | Age Group, Diagnosis, Therapeutic Agents Clinical Phase |
| KEY MARKET OPPORTUNITIES | Increasing aged population, Advancements in diagnostic tools, Growing demand for innovative therapies, Expansion of clinical trial pipelines, Rising awareness and education programs |
| KEY MARKET DYNAMICS | Increasing elderly population, Rising awareness and diagnosis, Limited treatment options, High unmet medical needs, Growing investment in research |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The expected overall market size of the US Geographic Atrophy GA Market in 2024 is valued at 5.75 billion USD.
In 2035, the market size of the US Geographic Atrophy GA Market is expected to reach 12.5 billion USD.
The expected CAGR for the US Geographic Atrophy GA Market from 2025 to 2035 is 7.314%.
For the age group above 60 years, the market size is valued at 3.45 billion USD in 2024.
In 2035, the market size for the age group above 75 years is expected to reach 5.0 billion USD.
Key players in the US Geographic Atrophy GA Market include Genentech, Novartis, Santen Pharmaceutical, and Regeneron Pharmaceuticals.
The growth opportunities in the US Geographic Atrophy GA Market are driven by an increasing elderly population and advancements in treatment strategies.
Regional trends indicate significant growth in the US due to an aging population and increased awareness of ophthalmic conditions.
The projected market size for the age group above 60 years is anticipated to be 7.5 billion USD in 2035.
The market faces challenges such as regulatory hurdles and competition in treatment innovations.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
